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ABSTRACT
Biomarker analysis has become routine practice in the treatment of non-small cell 
lung cancer (NSCLC). To ensure high quality testing, participation to external quality 
assessment (EQA) schemes is essential. This article provides a longitudinal overview 
of the EQA performance for EGFR, ALK, and ROS1 analyses in NSCLC between 2012 
and 2015.
The four scheme years were organized by the European Society of Pathology 
according to the ISO 17043 standard. Participants were asked to analyze the provided 
tissue using their routine procedures.
Analysis scores improved for individual laboratories upon participation to more 
EQA schemes, except for ROS1 immunohistochemistry (IHC). For EGFR analysis, scheme 
error rates were 18.8%, 14.1% and 7.5% in 2013, 2014 and 2015 respectively. For ALK 
testing, error rates decreased between 2012 and 2015 by 5.2%, 3.2% and 11.8% for the 
fluorescence in situ hybridization (FISH), FISH digital, and IHC subschemes, respectively. 
In contrast, for ROS1 error rates increased between 2014 and 2015 for FISH and IHC 
by 3.2% and 9.3%. Technical failures decreased over the years for all three markers.
Results show that EQA contributes to an ameliorated performance for most 
predictive biomarkers in NSCLC. Room for improvement is still present, especially 
for ROS1 analysis.
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INTRODUCTION
Over the last decades, personalized health care has 
become routine practice in the treatment of patients with 
non-small cell lung cancer (NSCLC) and several clinically 
important companion diagnostics have been implemented 
[1]. More specifically, testing for epidermal growth factor 
receptor (EGFR) variants in exons 18 to 21 is required by 
the Food and Drug Administration (FDA) and European 
Medicines Agency (EMA) prior to treatment of patients 
with EGFR tyrosine kinase inhibitors (TKIs) [2, 3]. 
Similarly, rearrangements of the anaplastic lymphoma 
kinase (ALK) and ROS proto-oncogene 1 tyrosine-protein 
kinase (ROS1) genes can predict the treatment outcome of 
TKIs as well [2, 3]. While the ALK gene has been included 
in the drug label of crizotinib since 2011, testing of ROS1 
rearrangements for treatment of patients with NSCLC has 
recently been added to the label of crizotinib by the FDA 
(March 2016) and by the EMA (September 2016) for first 
line therapy [4–6].
In 2012, lung cancer displayed the highest incidence 
of cancer onset and mortality worldwide [7], with 80% of 
cases due to NSCLC. High quality molecular testing in 
NSCLC is of utmost importance to prevent false-positive 
or false-negative results that could diminish patient 
prognosis or evoke unnecessary adverse treatment effects 
[7]. In addition, emerging techniques for molecular tumor 
analyses, such as next-generation sequencing (NGS) and 
the identification of novel molecular targets, pose new 
challenges. A lack of quality control could compromise 
correct test results [8–10]. As a result, laboratories are 
challenged to implement and also to maintain accurate test 
procedures to offer reliable results within an acceptable 
timeframe. Indeed, an increased error rate has been 
reported in 2013 following the introduction of full RAS 
testing for colorectal cancer [11]. Therefore, adequate 
training is necessary to avoid potential pitfalls, before 
a predictive molecular test is implemented in routine 
practice.
Participation to external quality assessment (EQA) 
schemes, also called proficiency testing, allows to monitor 
laboratory performance, to compare them on an inter-
laboratory level and to provide individual feedback. The 
aim of EQA schemes is to educate and support diagnostic 
laboratories to reach an accurate quality level of test results 
[7, 12]. In addition, EQA participation is an integral part of 
the quality framework of diagnostic laboratories, required 
by the International Organization for Standardization (ISO 
15189) [15] and the Clinical Laboratory Improvement 
Amendments [13].
In 2012 and 2013, the European Society of 
Pathology (ESP) introduced two pilot EQA schemes to 
evaluate the performance of ALK analysis in NSCLC [17]. 
In 2013, results showed a decreased error rate from 7.3% 
to 5.2% for ALK fluorescence in situ hybridization (FISH) 
and from 13.0% to 8.2% for ALK immunohistochemistry 
(IHC) as compared to 2012. In spite of these 
improvements, error rates and enumeration practices of the 
number of FISH nuclei, could still be ameliorated [17]. 
Results from other European EQA providers reported 
similar error rates for biomarker analysis in NSCLC, 
emphasizing the need for continued education [14–18].
The aim of this article is to analyze the results of 
four subsequent ESP Lung EQA schemes between 2012 
and 2015, as well as the laboratory improvement on a 
longitudinal level. A comparison will be made between 
three predictive biomarkers in NSCLC: EGFR, ALK and 
ROS1.
RESULTS
Over four years, 221 unique laboratories participated 
to the EGFR scheme, 243 to the ALK scheme (FISH 
and/or IHC) and 98 to the ROS1 scheme (FISH and/or 
IHC). In 2014, 31, 63 and 117 laboratories registered for 
three, two or one of these markers respectively. In 2015, 
35 laboratories participated to the schemes for all three 
markers, 62 laboratories participated to the schemes for 
two of three markers and 99 participants to only one of the 
markers. More than half of the laboratories were affiliated 
to a university (hospital) or were involved in both 
diagnostics and research (EGFR 56.6%, ALK, 56.8%, and 
ROS1 62.2%). Less than a third of the participants were 
affiliated to a general or private hospital (EGFR 24.4%, 
ALK 28.0%, and ROS1 21.4%) and a minority were 
private laboratories (EGFR 16.7%, ALK 13.2%, and ROS1 
13.3%) or industrial ones (EGFR 2.3%, ALK 2.1%, and 
ROS1 3.1%). Only a third of the institutes were accredited 
according to an international standard or national 
equivalent during their most recent EQA participation 
(EGFR 32.1%, ALK 32.5%, and ROS1 38.8%).
The individual performance of the laboratories 
improved when they participated to more EQA scheme 
years. Namely, their average performance score improved 
for two, three or four subsequent participations. (Table 
1). Only for the ROS1 IHC subscheme, the average 
performance score did not improve after repeated 
participation, unless one challenging positive ROS1 IHC 
case was not taken into account.
Error rates and the rates of technical failures during 
the EQA rounds for EGFR, ALK and ROS1 analysis are 
summarized in Figure 1 and Figure 2, respectively. For 
EGFR analysis, there is a decrease in error rate between 
2013 and 2015 from 18.8% towards 14.1% and 7.5% 
(Figure 1A). Erroneous results were mainly caused by 
missing the c.2369C>T p.(Thr790Met) variant. There 
was no correlation between false-negative results for 
this variant and the use of a specific methodology. 
Exclusion of these samples yielded error rates of 18.0%, 
14.5% and 6.4% in the 2013, 2014 and 2015 EGFR 
schemes, respectively. The estimation of the percentage 
of neoplastic cells for EGFR variant analysis displayed a 
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EGFR ALK FISH ALK IHC ROS1 FISH ROS1 IHC
N= % N= % N= % N= % N= %
1st 222 78.8 184 90.0 125 91.0 90 86.3 41 92.1
2nd 99 90.0 113 90.9 74 94.9 34 94.9 21 86.7 (97.1*)
3rd 48 91.0 60 93.7 51 96.7 NA NA NA NA
4th NA NA 24 95.4 18 100.0 NA NA NA NA
The scheme period included in the analysis, ranges from 2012 to 2015. The number represents the number of laboratories 
who participated to only one, two, three, or four years of EQA for that specific marker or subscheme. *Average score 
with the exclusion of a challenging positive ROS1 IHC case in 2015. Abbreviations: ALK, anaplastic lymphoma kinase; 
EGFR, epidermal growth factor receptor; EQA, external quality assessment; FISH, fluorescence in situ hybridization; IHC, 
immunohistochemistry; ROS1, proto-oncogene 1 tyrosine-protein kinase; N, number of laboratories; NA, not applicable 
because no EQA scheme was organized in this year.
Figure 1: Error rates (in percentage) across EQA scheme years. Errors rates include false-positive and false-negative results for 
EGFR, ALK and ROS1 and wrong variants for EGFR on the total number of analyzable samples. Educational samples, samples for which 
less than 50 nuclei were enumerated or for which a technical failure occurred, were not taken into account. (A) Error rates for EGFR variant 
analysis. N = 428 (2013), 1296 (2014), 1026 (2015). (B) Error rates for ALK analysis in different subschemes. IHC: n = 232 (2012), 576 
(2013), 864 (2014), 475 (2015); FISH: n = 269 (2012), 500 (2013), 833 (2014), 520 (2015); FISH digital: n = 260 (2012), 424 (2013), 291 
(2014), 522 (2015). (C) Error rates for ROS1 analysis in different subschemes. IHC: n = 310 (2014), 155 (2015); FISH: n = 372 (2014), 325 
(2015); FISH digital: n = 259 (2015). ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; EQA, external quality 
assessment; FISH, fluorescence in-situ hybridization; IHC, immunohistochemistry; N, number of participants; ROS1, proto-oncogene 1 
tyrosine-protein kinase.
Oncotarget20527www.oncotarget.com
high inter-observer variability, with an average standard 
deviation of 19.8% (n=142) and 21.1% (n=114) in 2014 
and 2015 for four and nine samples, respectively. The rate 
of technical errors for the EGFR scheme diminished from 
25.2% to 1.5% between 2013–2014 and increased again to 
5.2% in 2015 (Figure 2A). A great variety of methods was 
used for EGFR variant analysis over the years (Table 2). 
The use of laboratory-developed methods was gradually 
replaced by the implementation of NGS techniques.
For ALK analysis, there was a decrease in error 
rates between 2012 and 2015 for the three subschemes. 
For FISH digital, error rates decreased from 3.6% towards 
0.4% over time. For FISH and IHC on the tissue samples, 
error rates diminished from 7.3% to 2.1% and from 
13.0% to 1.3%, respectively. Error rates for IHC were 
higher compared to FISH in 2014, and compared to FISH 
digital analysis between 2012 and 2014 (Figure 1B). The 
percentage of technical failures remained stable for ALK 
FISH digital analysis, but decreased for ALK FISH from 
10.0% to 5.6%. For ALK IHC, a transient rise of 6.3% 
technical failures was observed in 2013.
For ALK IHC, a shift in the primary antibody clone 
was observed from 5A4 (60.9%) in 2012 towards D5F3 
(54.7%) in 2015 (Table 2). In 2015, 73 laboratories from 
25 countries submitted their stained IHC slides for the 
technical microscopic assessment. Their average technical 
score was 76.6%, or 3.83 on 5 (data not shown). A 
successful score of more than or equal to 4 out of 5 points 
was awarded to 48/73 (65.8%) laboratories. Seven out of 
73 participants (9.6%) were not successful with a score 
of 2 or less on a total of 5 points. The borderline score 
of 3/5 was awarded to 18 out of 73 (24.7%) laboratories. 
No correlation was observed of the staining score with a 
particular primary antibody clone, its dilution, incubation 
time, or the applied detection system.
For ALK FISH, the Vysis ALK break apart FISH 
probe (Abbott) was used by the majority of laboratories 
during all scheme years (Table 2). The evaluation of at 
Figure 2: Technical failure rates (in percentage) across EQA scheme years. Educational samples were not taken into account 
for calculation of the percentages. (A) Error rates for EGFR variant analysis. N= 428 (2013), 1296 (2014), 1026 (2015). (B) Error rates 
for ALK analysis in different subschemes. FISH: n = 269 (2012), 500 (2013), 928 (2014), 555 (2015); FISH digital: n = 260 (2012), 
424 (2013), 324 (2014), 555 (2015); IHC: n = 232 (2012), 576 (2013), 864 (2014), 475 (2015). (C) Error rates for ROS1 analysis in 
different subschemes. FISH: n = 448 (2014), 340 (2015); FISH digital: n = 272 (2015); IHC: n = 310 (2014), 155 (2015). ALK, anaplastic 
lymphoma kinase; EGFR, epidermal growth factor receptor; EQA, external quality assessment; FISH, fluorescence in-situ hybridization; 
IHC, immunohistochemistry; N, Number of participants; ROS1, proto-oncogene 1 tyrosine-protein kinase.
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Table 2: Overview of the used methods for EGFR, ALK and ROS1 analysis in the external quality assessment 
schemes between 2012 and 2015
Scheme year 2012 2013 2014 2015
Method for EGFR variant analysis NA N = 107 N = 144 N = 114
Commercial, non-NGS based NA 47 (43.9%) 95 (88.8%) 60 (56.1%)
With FP and FN NA 18 (16.8%) 56 (52.3%) 18 (16.8%)
Laboratory developed, non-NGS based NA 44 (41.1%) 42 (39.3%) 22 (20.6%)
With FP and FN NA 13 (12.1%) 24 (22.4%) 11 (10.3%)
NGS-based NA 1 (0.9%) 5 (4.7%) 33 (30.8%)
With FP and FN NA 0 (0.0%) 2 (1.9%) 7 (6.5%)
Combination NA 13 (12.1%) 2 (1.9%) 1 (0.9%)
With FP and FN NA 4 (3.7 %) 2 (1.9%) 0 (0.0%)
Unspecified NA 2 (1.9%) 0 (0.0%) 0 (0.0%)
With FP and FN NA 1 (0.9%) 0 (0.0%) 0 (0.0%)
Total evaluated NA 107 (100.0%) 144 (100.0%) 114 (100.0%)
Total with FP and FN NA 36 (33.6%) 84 (58.3%) 36 (31.6%)
Antibody for ALK IHC N = 29** N = 48** N = 96 N = 95
1A4 0 (0.0%) 0 (0.0%) 1 (1.0%) 4 (4.2%)
With FP and FN 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (1.1%)
4C5B8 0 (0.0%) 1 (2.0%) 0 (0.0%) 0 (0.0%)
With FP and FN 0 (0.0%) 1 (2.0%) 0 (0.0%) 0 (0.0%)
5A4 14 (46.7%) 18 (36.7%) 31 (32.3%) 35 (36.8%)
With FP and FN 5 (16.7%) 3 (6.1%) 11 (11.5%) 1 (1.1%)
ALK1 4 (13.3%) 3 (6.1%) 7 (7.3%) 4 (4.2%)
With FP and FN 3 (10.0%) 2 (4.1%) 3 (3.1%) 0 (0.0%)
D5F3 3 (10.0%) 26 (53.1%) 57 (59.4%) 52 (54.7%)
With FP and FN 2 (6.7%) 13 (26.5%) 15 (15.6%) 3 (3.2%)
SP8 2 (6.7%) 1 (2.0%) 0 (0.0%) 0 (0.0%)
With FP and FN 2 (6.7%) 1 (2.0%) 0 (0.0%) 0 (0.0%)
Unspecified 7 (23.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
With FP and FN 3 (10.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Total evaluated 30 (100%) 49 (100%) 96 (100.0%) 95 (100.0%)
Total with FP and FN 15 (50.0%) 20 (40.8%) 29 (30.2%) 5 (5.3%)
Method/kit used for ALK FISH N = 54* N = 100* N = 116 N = 111
Vysis ALK break apart FISH probe 
(Abbott) 41 (68.3%) 75 (72.8%) 79 (68.1%) 66 (59.5%)
With FP and FN 11 (18.6%) 16 (15.5%) 13 (11.2%) 8 (7.2%)
ALK LPS 019 breakapart probe 
(Cytocell) 0 (0.0%) 0 (0.0%) 1 (0.9%) 2 (1.8%)
With FP and FN 0 (0.0%) 0 (0.0%) 1 (0.9%) 0 (0.0%)
(Continued )
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Scheme year 2012 2013 2014 2015
Method/kit used for ALK FISH N = 54* N = 100* N = 116 N = 111
ALK FISH DNA Probe, Split Signal 
(Dako) 8 (13.3%) 10 (9.7%) 11 (9.5%) 13 (11.7%)
With FP and FN 3 (5.1%) 0 (0.0%) 2 (1.7%) 1 (0.9%)
Repeat-Free Poseidon ALK (2p23) Break 
Probe (Kreatech Diagnostics) 1 (1.7%) 3 (2.9%) 4 (3.4%) 3 (2.7%)
With FP and FN 1 (1.7%) 0 (0.0%) 2 (1.7%) 0 (0.0%)
Repeat-Free Poseidon ALK/EML4 
t(2;2) inv(2) Fusion Probe (Kreatech 
Diagnostics)
4 (6.7%) 1 (1.0%) 0 (0.0%) 0 (0.0%)
With FP and FN 0 (0.0%) 1 (1.0%) 0 (0.0%) 0 (0.0%)
Master Diagnostica (not further 
specified) 0 (0.0%) 1 (1.0%) 0 (0.0%) 0 (0.0%)
With FP and FN 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
XT ALK Break Apart Probe 
(MetaSystems) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (0.9%)
With FP and FN 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
ZytoLight SPEC ALK Dual Color Break 
Apart Probe (ZytoVision) 0 (0.0%) 1 (1.0%) 6 (5.2%) 14 (12.6%)
With FP and FN 0 (0.0%) 0 (0.0%) 1 (0.9%) 0 (0.0%)
ZytoLight SPEC ALK/EML4 TriCheck 
Probe (ZytoVision) 5 (8.3%) 7 (6.8%) 15 (12.9%) 12 (10.8%)
With FP and FN 1 (1.7%) 3 (2.9%) 5 (4.3%) 0 (0.0%)
Zytomed (not further specified) 0 (0.0%) 2 (2.0%) 0 (0.0%) 0 (0.0%)
With FP and FN 0 (0.0%) 1 (1.0%) 0 (0.0%) 0 (0.0%)
Unspecified 1 (1.7%) 3 (2.9%) 0 (0.0%) 0 (0.0%)
With FP and FN 1 (1.7%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
Total evaluated 60 (100.0%) 103 (100.0%) 116 (100.0%) 111 (100.0%)
Total with FP and FN 17 (28.3%) 21 (20.4%) 24 (20.7%) 9 (8.1%)
Antibody ROS1 IHC NA NA N = 31 N = 31
D4D6 NA NA 31 (100.0%) 31 (100.0%)
With FP and FN NA NA 7 (22.6%) 17 (54.8%)
Methods/kit used for ROS1 FISH N = 56* N = 68
Vysis 6q22 ROS1 Break Apart FISH 
Probe (Abbott) NA NA 4 (7.0%) 6 (8.8%)
With FP and FN NA NA 1 (1.8%) 1 (1.5%)
Vysis LSI ROS1 (Tel) Spectrum Orange 
Probe (Abbott); Vysis LSI ROS1 (Cen) 
Spectrum Green Probe (Abbott)
NA NA 2 (3.5%) 3 (4.4%)
With FP and FN NA NA 0 (0.0%) 0 (0.0%)
(Continued )
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Scheme year 2012 2013 2014 2015
Methods/kit used for ROS1 FISH N = 56* N = 68
Vysis LSI ROS1 (Tel) Spectrum Orange 
Probe (Abbott) NA NA 9 (15.8%) 9 (13.2%)
With FP and FN NA NA 1 (1.8%) 5 (7.4%)
ROS1 breakapart Probe (Cytocell) NA NA 3 (5.3%) 4 (5.9%)
With FP and FN NA NA 0 (0.0%) 1 (1.5%)
SureFISH ROS1 break apart (Dako) NA NA 2 (3.5%) 4 (5.9%)
With FP and FN NA NA 0 (0.0%) 1 (1.5%)
REPEAT-FREE POSEIDON ROS1 
(6q22) Break FISH Probe (Kreatech 
Diagnostics)
NA NA 12 (21.1%) 9 (13.2%)
With FP and FN NA NA 0 (0.0%) 3 (4.4%)
6q22 (ROS1) DNA split FISH Probe 
(Medimiks) NA NA 0 (0.0%) 1 (1.5%)
With FP and FN NA NA 0 (0.0%) 0 (0.0%)
ZytoLight SPEC ROS1 - not specified 
(ZytoVision) NA NA 0 (0.0%) 1 (1.5%)
With FP and FN NA NA 0 (0.0%) 1 (1.5%)
ZytoLight SPEC ROS1 Dual Color Break 
Apart Probe (ZytoVision) NA NA 23 (40.4%) 30 (44.4%)
With FP and FN NA NA 2 (3.5%) 2 (2.9%)
ZytoLight SPEC ROS1/CEN 6 Dual 
Color Probe (ZytoVision) NA NA 1 (1.8%) 1 (1.5%)
With FP and FN NA NA 1 (1.8%) 0 (0.0%)
Unspecified NA NA 1 (1.8%) 0 (0.0%)
With FP and FN NA NA 1 (1.8%) 0 (0.0%)
Total evaluated NA NA 60 (100.0%) 68 (100.0%)
Total with FP and FN NA NA 5 (8.8%) 14 (20.6%)
For ALK and ROS1 FISH, only laboratories that tested the regular FISH slides were taken into account, digital images were 
not considered. * Laboratories could enter two kits in the results form. ** One Laboratory evaluated two antibodies and was 
counted twice. Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; FP, false-
positive; FN, false-negative; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NA, not applicable 
because no EQA scheme was organized in this year; N, number of laboratories; NGS, next-generation sequencing; ROS1, 
proto-oncogene 1 tyrosine-protein kinase.
least 50 neoplastic nuclei for ALK FISH and FISH digital 
improved across the subsequent EQA scheme years (Table 
3). The percentage of samples in which less than 50 nuclei 
were counted was higher for the digital FISH cases as 
compared to FISH. No correlation was observed between 
the number of nuclei counted and the scheme error rate. 
For the negative cases, a distinction was made between 
counting less than 50 or less than 43 nuclei, as counting 
less than 43 nuclei could result in a change of outcome 
when the unevaluated 7 nuclei are positive, eventually 
exceeding the 15% cutoff for positivity.
In contrast to EGFR and ALK analysis, error rates 
for ROS1 analysis increased between 2014 and 2015. For 
FISH and IHC the rates increased from 1.1% to 4.3% and 
4.3% to 13.6%, respectively (Figure 1C). The ROS1 FISH 
digital cases were introduced in 2015, and an error rate of 
3.2% was observed. Similar to ALK analysis, error rates 
were higher for ROS1 IHC, compared to ROS1 FISH in 
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Table 3: Fraction of samples (%) for which less than 50 nuclei were enumerated by the participants of the FISH and 
FISH digital subschemes for ALK and ROS1, and the fraction (%) of them including false-positive, false-negative or 
technical failures
Subscheme ALK FISH ALK FISH digital ROS1 FISH ROS1 FISH digital
Scheme year 2012 2013 2014 2015 2012 2013 2014 2015 2014 2015 2015
<50 nuclei 































































































































































































Educational cases are not included in the total sample number. For the negative cases, a distinction was made between 
counting less than 50 or even less than 43 nuclei, since counting less than 43 nuclei could result in a change of outcome 
when the unevaluated 7 nuclei are positive, eventually exceeding the 15% cutoff for positivity. Abbreviations: ALK, 
anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization; ROS1, proto-oncogene 1 tyrosine-protein kinase; FP, 
false-positive; FN, false–negative; Nr, Number
2014 and 2015 and ROS1 FISH digital in 2015. In contrast 
to the error rates, technical failures for ROS1 subschemes 
diminished between the two EQA rounds, and were higher 
for FISH and FISH digital analysis as compared to IHC 
(Figure 2C).
In 2014–2015, the D4D6 primary antibody clone 
was the only one routinely used for the detection of 
ROS1 expression (Table 2). In spite of the same clone, the 
number of laboratories obtaining a false-positive or false-
negative result increased from 7/31 (22.6%) towards 17/31 
(54.8%) (data not shown). For FISH, the ZytoLight SPEC 
ROS1 Dual Color Break Apart Probe (ZytoVision) was the 
most popular for ROS1 rearrangement analysis during both 
EQA scheme years (Table 2). Similar to the ALK scheme, 
the evaluation of at least 50 neoplastic nuclei for FISH 
and FISH digital improved across the subsequent EQA 
schemes (Table 3), although more nuclei were counted in 
the FISH digital images than in FISH samples.
DISCUSSION
Since 2012, ESP EQA schemes have been organized 
to assess and improve the current state of biomarker testing 
in NSCLC. In 2016, ROS1 analysis has been added as a 
requirement to the label of crizotinib [5, 6], which called 
to re-evaluate the performance of laboratories during the 
four EQA scheme years.
The EQA results demonstrate that individual 
laboratories improve their testing quality if they participate 
to more subsequent EQA scheme years. (Table 1). In 
addition, graphs display a general decrease in error rates 
for EGFR and ALK analysis and an increase in errors for 
ROS1 analysis (Figure 1), across scheme years. These 
findings suggest that the feedback provided at the end of an 
EQA scheme have positively influenced the participants’ 
test performance. However, increased experience can also 
be an improving factor, although difficult to quantify as 
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routine diagnostics is a continuously developing field 
parallel to EQA participation. Indeed, further research is 
needed to investigate the underlying causes of laboratory 
errors, and how sample complexity can contribute to these. 
However, the high number of participants allows us to 
reliably estimate the average error rate. While other EQA 
results in NSCLC have been reported [21–23, 25], unique 
to our data is the longitudinal comparison between scheme 
years, markers and techniques.
Despite the improvement of EGFR variant analysis 
over the years (Figure 1A), the remaining high error 
rates in 2015 were mostly due by the misidentification 
of c.2369C>T p.(Thr790Met), although unrelated to the 
technique used. Between 2013–2015, five cases (two 
resections and three cell-lines) including this variant 
were included, and more errors were observed in the 
resection specimens compared to cell-lines. As this 
variant usually occurs at low frequencies in routine, and 
allele frequencies varied between 10%-50%, the exact 
reason why this variant seems to be difficult remains to 
be elucidated. Previously, a high percentage of false-
negative results was also observed for cell-lines with this 
variant in three consecutive EQA scheme years in France 
[24]. Reliable detection of c.2369C>T p.(Thr790Met) 
is clinically important as it is present in 50% of treated 
EGFR-mutated tumors, and confers resistance to first 
and second generation TKI’s [28]. Moreover, the FDA 
and EMA approved osimertinib as a third generation TKI 
for the treatment of progressive NSCLC containing this 
variant, in 2015 and 2016 respectively [29, 30]. Additional 
awareness is thus needed, and EQA providers should 
routinely include challenging samples in EQA schemes, 
if necessary by the inclusion of cell lines if resection 
material is limited available. Moreover, for EGFR 
analysis a large inter-observer variability in the estimation 
of the percentage of neoplastic cells in the samples was 
observed. Pictures of the tissue area selected for DNA 
extraction that were optionally provided by some of the 
participants, reveal that the marked area differs among 
participants. This variability is well-known in molecular 
pathology, and additional research is required to evaluate 
the different methods for neoplastic cell estimation and 
their influence on the performance score.
For ALK analysis, error rates displayed an obvious 
improvement for all subschemes and years. Error rates 
were higher for ALK IHC analysis, compared to the 
FISH and the FISH digital subscheme, in line with 
previously reported EQA results in 2012 and 2013 [17]. 
Immunohistochemistry is frequently used as a screening 
tool prior to FISH confirmation, and although some 
studies describe an equal sensitivity, some discrepancies 
between both techniques have been reported also [31]. For 
ALK IHC, a shift occurred from the 5A4 towards the D5F3 
antibody clone as the D5F3 CDx IHC assay (Ventana) 
was approved by the FDA in the USA and China since 
2015, and pathologists were provided with a guide for the 
interpretation of a binary score for this antibody clone. 
In addition, several studies [32–34] revealed a similar 
sensitivity (96-100%) of both the 5A4 and D5F3 clones 
for ALK IHC staining.
During the technical assessment for ALK IHC, no 
correlation was observed between the staining quality or 
the ALK IHC performance and the used antibody clone, 
the process of epitope retrieval, incubation time and 
temperature, or detection system. This is in contrast to 
recently published EQA results from the United Kingdom 
National External Quality Assessment Service [35], 
for which a worse performance was related to specific 
detection methods. However, the included sample types 
in the ESP EQA scheme and distribution of methodologies 
differ, so longitudinal data of the next technical evaluations 
are necessary to provide insight into recurrent difficulties 
for ALK IHC.
For ALK FISH analysis, error rates were higher 
for FISH as for the interpretation of the digital images. 
This can be explained by the fact that FISH encompasses 
additional factors related to sample quality and assay 
execution, making this technique more error prone 
compared to interpretation only. Besides the reduced error 
rate, digital FISH also showed a decreased variation in 
the percentage of observed positive signals as compared 
to FISH (data not shown), suggesting that a factor of 
tissue heterogeneity might have been involved. As for 
IHC, the most frequently used methodology is the VYSIS 
ALK Break Apart FISH Probe Kit (Abbott) which is the 
FDA approved test to determine ALK status. In addition, 
it is recommended to enumerate at least 50 nuclei 
before considering a FISH or FISH digital case as either 
positive or negative [18–20]. Our results demonstrate 
an improvement in enumeration practices across 
scheme years (Table 3), in line with the observations 
of 2012 and 2013 [17]. Surprisingly, in contrast to the 
recommendations, participants evaluating less than 
50 nuclei in a positive case or less than 43 nuclei in a 
negative case did not perform worse in the EQA schemes. 
This could be due to the fact that equivocal cases are 
denoted as educational. Counting less nuclei is especially 
striking for the digital images as they were preselected and 
validated to contain at least 50 evaluable nuclei, and all 
participants receive access to identical cases. However, 
digital FISH images might not follow the same laboratory 
course as the regular slides [17], hence the difference 
for ROS1 testing. Error rates increased between 2014 
and 2015 for both FISH and IHC (Figure 1C). First of 
all, this is explained by the fact that ROS1 was not yet 
a routinely used predictive biomarker in 2014–2015, and 
participants might still be in the learning/validation phase 
of the analysis. In 2013, a similar increased error rate was 
also reported after the inclusion of NRAS to the label of 
cetuximab and panitumumab for treatment of patients with 
metastatic colorectal cancer [13]. Also, guidelines did not 
or only briefly mention ROS1 specific recommendations 
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analysis 2013 107 4 4 cell lines 1 5 1 WT, 3 mut 0 WT, 0 mut
2014 144 9 5 cell lines, 4 resections 2 5 2 WT, 7 mut 0 WT, 0 mut
2015 114 10 10 resections 2 5 5 WT, 4 mut 0 WT, 1 mut
ALK IHC 2012 29 8 4 cell lines, 4 resections 2 5 4 +ve, 4 -ve 0 +ve, 0 -ve
2013 48 12 6 cell lines, 6 resections 1 5 3 +ve, 9 -ve 0 +ve, 0 -ve
2014 96 10 4 cell lines, 6 resections 2 3 2 +ve, 7 -ve 1 +ve, 0 -ve
2015 95 5 5 resections 2 3 2 +ve, 3 -ve 0 +ve, 0 -ve
ALK FISH 2012 54 8 4 cell lines, 4 resections 2 5 3 +ve, 2 -ve 1 +ve, 2 -ve
2013 100 12 6 cell lines, 4 resections 1 5 2 +ve, 3 -ve 2 +ve, 5 -ve
2014 116 10 4 cell lines, 6 resections 1 5 2 +ve, 6 -ve 1 +ve, 1 -ve
2015 111 5 5 resections 1 5 2 +ve, 3 -ve 0 +ve, 0 -ve
ALK FISH 





NA NA 2 +ve, 2 -ve 0 +ve, 0 -ve
2013 106 4 2 +ve, 2 -ve 0 +ve, 0 -ve
2014 81 4 2 +ve, 2 -ve 0 +ve, 0 -ve
2015 111 5 2 +ve, 3 -ve 0 +ve, 0 -ve
ROS1 IHC 2014 31 10 4 cell lines, 6 resections 2 3 2 +ve, 8 -ve 0 +ve, 0 -ve
2015 31 6 5 resections 2 3 2 +ve, 3 -ve 1 +ve, 0 -ve
ROS1 FISH 2014 56 10 4 cell lines, 6 resections 2 5 1 +ve, 7 -ve 1 +ve, 1 -ve
2015 68 6 1 cell line,5 resections 1 5 2 +ve, 3 -ve 1 +ve, 0 -ve
ROS1 FISH 





NA NA 1 +ve, 3 -ve 1 +ve, 0 -ve
The schemes of 2012 and 2013 are two pilot EQA schemes for which the set-up has previously been reported [17]. 
The following variants were part of the EGFR variant analysis schemes: c.2155G>A p.(Gly719Ser), c.2156G>C 
p.(Gly719Ala), c.2235_2249del p.(Glu746_Ala750del), c.2327G>A p.(Arg776His), c.2369C>T p.(Thr790Met), c.2573T>G 
p.(Leu858Arg), c.2300_2308dup p.(Ala767_Val769dup). Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, 
epidermal growth factor receptor; EQA, external quality assessment; FISH, fluorescence in situ hybridization; IHC, 
immunohistochemistry; mut, mutated; NA, not applicable; Nr, Number; ROS1, proto-oncogene 1 tyrosine-protein kinase; 
WT, wild-type; +ve, positive; -ve, negative.
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until 2016 [36–37]. Secondly, in 2014 four of ten cases 
consisted of cell-lines, whereas in 2015 all five distributed 
cases were resection specimens, suggesting that tissue 
heterogeneity could play a role. To ensure the adequacy 
of the resection material, the ESP selects clinical samples 
containing at least 30% neoplastic cells, and provides 
H&E stained slides to the participants.
Similar to the ALK scheme, error rates were higher 
for ROS1 IHC as compared to FISH or FISH digital 
analysis. First of all, in 2015 one particular ROS1 positive 
case has led to an increased error rate for IHC, as 15 of 31 
laboratories reported a false-negative result. Although a 
consensus score of at least 75% was not reached, the case 
was not denoted as educational based on the absence of 
problems during validation, the adequate FISH results and 
re-evaluation by the assessors. Leaving out this sample, 
an error rate of 4.8% instead of 13.6% could be observed 
(Figure 1C, Black triangle). Nevertheless, with recent 
changes in the status of crizotinib, ROS1 test requests 
are expected to increase over time and quality of the test 
results must be assured.
Focusing on the technical failures, the increase for 
EGFR analysis could be explained by an increase of NGS 
users between 2014 and 2015 from 4.2% to 28.9% (Table 
2). Although in 2015 less genotyping errors were made 
by the NGS users (χ2 test, p=0.129), the percentage of 
laboratories with technical errors was higher for this group 
with 30.3% (n=33) as compared to non-NGS users with 
23.5% (n=81), while not significant (χ2 test, p=0.447). 
Previously, the French EQA results also revealed increased 
error rates over time, among other things due to the rising 
number of genes to be analyzed in parallel [24]. For 
ALK and ROS1, technical failures were less abundant for 
IHC, compared to the FISH digital and FISH subscheme. 
This could be explained by four reasons: (1) the fact that 
although interpretation errors might occur, IHC is a more 
routinely used method with automated steps as compared 
to FISH. (2) In 2013, a tissue micro-array was provided 
for ALK IHC and many participants indicated a loss of 
one of the six provided cores which was subsequently 
considered as a technical failure. (3) While several cases 
were considered educational for ALK FISH, this was not 
the case for ALK IHC (Table 4), resulting in an elevated 
number of technical failures for this subscheme. (4) For 
FISH digital analysis the distance between signals may 
be difficult to estimate or may be overlapping in the 
vertical axis, which could also result in a higher number 
of participants who denote the sample as not evaluable as 
compared to FISH analysis [31]. However, all participants 
received access to identical FISH digital images, and cases 
were included if at least 75% of participants were able to 
correctly them.
To conclude, results of this study illustrate that EQA 
helps to uncover problems in a timely manner. Importantly, 
this study also highlights that on an individual laboratory 
level, more participations are correlated with an improved 
performance of biomarker analysis in NSCLC. Although, 
the exact mechanism might be difficult to elucidate as 
molecular pathology is a field of continuous evolvement 
and gained experience. Room for improvement is still 
apparent, especially for ROS1 IHC or the detection of 
low frequency resistance mutations like c.2369C>T 
p.(Thr790Met). A large variety was also observed in 
the estimation of the neoplastic cell content and in the 
different analysis methods.
To improve error rates for biomarker analysis, 
frequent EQA participation is essential to strive to high 
quality biomarker analyses irrespective of the used 
methodologies to ensure patient safety at all times.
In addition, future research needs to be performed 
to get more insight into the exact causes of the error 
rates linked to specific variants/methodologies, and how 
sample characteristics and the different ways of neoplastic 
cell estimation contribute to these problems. The yearly 
organization of these EQA schemes provides an essential 
platform to evaluate these topics in a longitudinal manner, 
and based on the findings reported in this manuscript, 
projects are currently being set-up. Ultimately these will 
result in more detailed laboratory guidelines to overcome 
specific or systematic challenges.
MATERIALS AND METHODS
The set-up of each ESP Lung EQA scheme was 
determined beforehand by a steering committee of 
international experts in molecular diagnostics, according 
to the guideline on the requirements of external quality 
assessment programs in molecular pathology [14]. The 
organization by the coordination center was performed in 
accordance with the ISO 17043 standard for conformity 
assessment of proficiency testing [26]. Formalin-fixed 
paraffin-embedded (FFPE) samples were collected and 
the experts made a final selection to be provided to the 
participants. A minimum of three reference laboratories 
assessed the adequacy of each sample using their routinely 
applied detection methods.
Participants were able to register, submit data and 
access their results via a password-protected central 
database, accessible through the ESP Lung EQA scheme 
website (http://lung.eqascheme.org). Registration was 
open to all laboratories world-wide and allowed to select 
different subschemes depending on the marker (EGFR, 
ALK and/or ROS1) and method (variant analysis, FISH 
and/or IHC) of interest. An overview of the samples 
distributed during each subscheme is represented in 
Table 4.
Between 2012 and 2014, participants of the FISH 
subscheme could optionally interpret five additional 
digital FISH images, which was made mandatory in 2015. 
These digital cases were created with the Vysis ALK Break 
Apart FISH Probe kit (Abbott) for ALK and the Vysys 
6q22 ROS1 Break Apart FISH probe RUO kit (Abbott) 
Oncotarget20535www.oncotarget.com
for ROS1, and captured images were validated by the 
reference laboratories. The images were made available 
online, along with the digitized hematoxylin and eosin 
stained slides for pathologist review of the FFPE material. 
Access was provided via the ESP Lung EQA website 
and the PathXL platform (PathXL, Belfast, Northern 
Ireland; http://www.pathxl.com/). In 2015, the ALK IHC 
subscheme was expanded by a technical microscopic 
assessment of the slides’ immunohistochemical staining 
by a team of pathologists.
Participants were asked to analyze the samples using 
their routine testing procedures. In case of EGFR analysis, 
an estimation of the percentage of neoplastic cells in the 
tissue should be given. For ALK/ROS1 FISH, participants 
were asked to evaluate at least 50 nuclei and to apply a 
15% threshold for positivity as recommended [19]. To 
reflect clinical practice, the deadline for submission of 
the results was 14 calendar days after sample receipt 
[27]. Additional information regarding laboratory 
characteristics and the applied methods was requested via 
the online submission system on their account.
The scheme results were evaluated by a team of 
international assessors for each individual subscheme 
in agreement with the guidelines on the requirements of 
EQA programs in molecular pathology [20]. Samples 
for which more than 25% of participants were not able 
to obtain conclusive results were considered educational 
and were excluded from the performance score. For 
other samples, laboratories could obtain a maximum of 
two points for a correct outcome. During the technical 
assessment, a general technical score on five points was 
provided for the five slides provided in the scheme. 
Successful participation was defined as all laboratories 
with equal to or more than four on five. A score of three 
was considered borderline. Laboratories could access their 
results and individual feedback from current and previous 
EQA schemes via their account.
Error rates for a subscheme were calculated by 
summating the total number of false-positive and false-
negative results or wrong variants, divided by the total 
number of samples for which a result has been obtained 
by all participants of the subscheme, and were presented 
in a descriptive manner on sample level. For the FISH and 
FISH digital subschemes, only samples for which more 
than or equal to 50 nuclei were counted were included. 
The rate of technical failures was determined by dividing 
the total number of samples for which a laboratory 
reported a not-contributive result, by the total number 
of samples analyzed. For every scheme year between 
2012 and 2015, the error and technical failure rates are 
represented per marker (ALK, ROS1, EGFR) and method 
of analysis (variant analysis, FISH, IHC). To evaluate 
the improvement of the individual laboratories upon 
participation to EQA, their average genotyping score was 
calculated, after participation to only one, two, three or 
four subsequent EQA schemes.
Graphs were created using GraphPad Prism version 
7.00 (GraphPad Software Inc, La Jolla, CA, USA). The 
tables representing the methods used by the participants 
to analyze the samples are displayed as reported by the 
participants.
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